Published in J Natl Cancer Inst on December 20, 1989
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Explaining risks: turning numerical data into meaningful pictures. BMJ (2002) 8.28
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet (1998) 5.95
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med (2008) 4.81
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst (2008) 4.52
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
A theory of medical decision making and health: fuzzy trace theory. Med Decis Making (2008) 3.67
Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med (2010) 3.57
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst (2010) 3.39
Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol (2012) 3.24
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer (2007) 3.15
Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med (2014) 3.09
Predicting risk of dementia in older adults: The late-life dementia risk index. Neurology (2009) 2.92
Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res (2011) 2.86
Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information. J Natl Cancer Inst (2010) 2.82
Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res (2007) 2.71
Net reclassification indices for evaluating risk prediction instruments: a critical review. Epidemiology (2014) 2.67
Testing for improvement in prediction model performance. Stat Med (2013) 2.62
The search for cancer risk factors: when can we stop looking? Am J Public Health (2001) 2.62
Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst (2011) 2.61
Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol (2008) 2.56
Familial breast cancer. BMJ (1994) 2.54
PancPRO: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol (2007) 2.45
Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst (2009) 2.35
Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis (2009) 2.26
Model for individualized prediction of breast cancer risk after a benign breast biopsy. J Clin Oncol (2015) 2.25
Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet (2003) 2.24
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med (2014) 2.20
Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology (2010) 2.13
Confirmation of family cancer history reported in a population-based survey. J Natl Cancer Inst (2011) 2.13
Patterns of breast magnetic resonance imaging use in community practice. JAMA Intern Med (2014) 2.08
Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat (2013) 2.07
Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol (2008) 2.06
Effects of communicating individual risks in screening programmes: Cochrane systematic review. BMJ (2003) 2.06
Risk prediction using genome-wide association studies. Genet Epidemiol (2010) 2.03
External validity of risk models: Use of benchmark values to disentangle a case-mix effect from incorrect coefficients. Am J Epidemiol (2010) 2.03
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol (2011) 2.00
Understanding risk and lessons for clinical risk communication about treatment preferences. Qual Health Care (2001) 1.99
Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet (2004) 1.96
Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst (2011) 1.94
A clinical risk stratification tool for predicting treatment resistance in major depressive disorder. Biol Psychiatry (2013) 1.90
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res (2004) 1.85
Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet (2003) 1.85
Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer (2008) 1.84
Problems with risk reclassification methods for evaluating prediction models. Am J Epidemiol (2011) 1.84
Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med (2009) 1.83
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 1.77
Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol (2009) 1.76
Influence of stressors on breast cancer incidence in the Women's Health Initiative. Health Psychol (2009) 1.75
Screening mammography in older women: a review. JAMA (2014) 1.70
Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer (2008) 1.65
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res (Phila) (2012) 1.63
Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ (2003) 1.63
Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res (Phila) (2011) 1.62
Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. Eur J Hum Genet (2012) 1.62
The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer (2008) 1.62
Beyond mammography: new frontiers in breast cancer screening. Am J Med (2013) 1.61
Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs. Patient Educ Couns (2008) 1.60
The privatization of risk. Am J Public Health (2001) 1.59
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol (2009) 1.54
Environmental pollutants and breast cancer. Environ Health Perspect (2003) 1.53
A Perturbation Method for Inference on Regularized Regression Estimates. J Am Stat Assoc (2012) 1.53
Risk-benefit profiles of women using tamoxifen for chemoprevention. J Natl Cancer Inst (2014) 1.51
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc (2010) 1.51
Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst (2010) 1.51
Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst (2011) 1.51
Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg (2014) 1.50
Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med (2011) 1.49
eHealth research from the user's perspective. Am J Prev Med (2007) 1.49
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat (2010) 1.47
Comparison of family history and SNPs for predicting risk of complex disease. PLoS Genet (2012) 1.47
Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res (2012) 1.47
Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst (2009) 1.47
Validation of a breast cancer risk prediction model developed for Black women. J Natl Cancer Inst (2013) 1.46
Communicating risk to patients and the public. Br J Gen Pract (2012) 1.42
Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging (2008) 1.41
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Outcomes of multimodality breast screening for women at increased risk of familial breast cancer. World J Surg (2010) 1.38
Clinical utility of family history for cancer screening and referral in primary care: a report from the Family Healthware Impact Trial. Genet Med (2011) 1.38
Molecular targets for cancer chemoprevention. Nat Rev Drug Discov (2009) 1.38
Genetic susceptibility to pancreatic cancer. Mol Carcinog (2012) 1.36
Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol (2009) 1.35
Genetic assessment of breast cancer risk in primary care practice. Am J Med Genet A (2009) 1.35
Rating the risk factors for breast cancer. Ann Surg (2003) 1.35
Oestrogen exposure and breast cancer risk. Breast Cancer Res (2003) 1.34
Benign breast disease, mammographic breast density, and the risk of breast cancer. J Natl Cancer Inst (2013) 1.34
Identification and extraction of family history information from clinical reports. AMIA Annu Symp Proc (2008) 1.34
Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet (2013) 1.33
Taking Stock of Unrealistic Optimism. Perspect Psychol Sci (2013) 1.33
Risk factors for oesophageal squamous dysplasia in adult inhabitants of a high risk region of China. Gut (2005) 1.32
Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol (1985) 11.38
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
The ecological fallacy. Am J Epidemiol (1988) 6.38
Randomized clinical trials. Perspectives on some recent ideas. N Engl J Med (1976) 5.86
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst (1995) 5.35
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med (1980) 4.90
Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med (1986) 4.18
Characteristics of women with dysplasia or carcinoma in situ of the cervix uteri. Br J Cancer (1980) 4.11
The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med (1989) 3.77
Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica (1997) 3.67
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev (2001) 3.40
Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer (1993) 3.33
The genesis of dermatoglyphics. J Pediatr (1969) 3.07
Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer (1973) 2.91
State laws on youth access to tobacco in the United States: measuring their extensiveness with a new rating system. Tob Control (1998) 2.85
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80
Systematic biases in functional status assessment of elderly adults: effects of different data sources. J Gerontol (1984) 2.77
Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet (1998) 2.74
Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer (2006) 2.68
A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer (1979) 2.67
Random digit dialing in selecting a population-based control group. Am J Epidemiol (1984) 2.64
Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer (2000) 2.62
Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer (1985) 2.59
A population-based case-control study of childhood leukemia in Shanghai. Cancer (1988) 2.59
A prospective study of diet quality and mortality in women. JAMA (2000) 2.52
Mammographic densities and risk of breast cancer. Cancer (1991) 2.47
Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst (2001) 2.43
Characteristics of women with and without breast augmentation. JAMA (1997) 2.26
On design considerations and randomization-based inference for community intervention trials. Stat Med (1996) 2.25
A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet (1997) 2.22
A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol (1988) 2.20
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (2001) 2.12
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst (1996) 2.12
Multipoint linkage analysis in neurofibromatosis type I: an international collaboration. Am J Hum Genet (1989) 2.04
Geographic variation in mortality from breast cancer among white women in the United States. J Natl Cancer Inst (1995) 2.03
Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst (1985) 2.00
Epidemiology of uterine cervical cancer. J Chronic Dis (1986) 1.97
Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med (1989) 1.94
The epidemiology of cervical carcinogenesis. Cancer (1995) 1.88
Alcohol consumption and breast cancer in the epidemiologic follow-up study of the first National Health and Nutrition Examination Survey. N Engl J Med (1987) 1.87
Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl (1995) 1.83
Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer (1970) 1.82
Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol (2001) 1.82
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep (1983) 1.81
Malignancy in neurofibromatosis. Adv Neurol (1981) 1.81
Breast cancer risk factors among screening program participants. J Natl Cancer Inst (1979) 1.81
Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr (1985) 1.81
Why data bases should not replace randomized clinical trials. Biometrics (1980) 1.81
Relative and attributable risk for cervical cancer: a comparative study in the United States and Italy. Int J Epidemiol (1990) 1.77
Alcohol consumption and breast cancer risk among women under age 45 years. Epidemiology (1997) 1.76
Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst (1996) 1.76
Body size and breast cancer risk among women under age 45 years. Am J Epidemiol (1996) 1.75
Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med (1987) 1.73
Evidence of a healthy estrogen user survivor effect. Epidemiology (1995) 1.72
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg (1989) 1.72
Late effects of therapy in adult survivors of osteosarcoma and Ewing's sarcoma. Med Pediatr Oncol (1992) 1.67
Barrier and spermicidal contraceptive methods and risk of invasive cervical cancer. Epidemiology (1990) 1.67
Patterns of inheritance in hypertrophic cardiomyopathy: assessment by M-mode and two-dimensional echocardiography. Am J Cardiol (1984) 1.67
Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer (1996) 1.66
Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst (1987) 1.62
How Many Subjects Does It Take To Do A Regression Analysis. Multivariate Behav Res (1991) 1.61
Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol (1997) 1.61
Dietary relationships with early onset (under age 45) breast cancer in a case-control study in the United States: influence of chemotherapy treatment. Cancer Causes Control (1997) 1.59
Aspects of statistical design for the Community Intervention Trial for Smoking Cessation (COMMIT). Control Clin Trials (1992) 1.58
Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer (1970) 1.58
Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer (1987) 1.58
Factors influencing the age at natural menopause. J Chronic Dis (1987) 1.57
Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol (1998) 1.56
Further delineation of the Baller-Gerold syndrome. Am J Med Genet (1993) 1.56
Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer (1986) 1.55
Effect of twinship on incidence of cancer of the testis, breast, and other sites (Sweden). Cancer Causes Control (1995) 1.55
Orchiectomy for advanced prostatic carcinoma. A reevaluation. Urology (1973) 1.53
Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Br J Cancer (2006) 1.53
Comparison of telephone sampling and area sampling: response rates and within-household coverage. Am J Epidemiol (2001) 1.51
Risk of cancer in women receiving hormone replacement therapy. Int J Cancer (1989) 1.49
Medical geneticists confront ethical dilemmas: cross-cultural comparisons among 18 nations. Am J Hum Genet (1990) 1.49
Pregnancy characteristics and maternal risk of breast cancer. Epidemiology (1998) 1.48
Determinants of genital human papillomavirus infection in low-income women in Washington, D.C. Sex Transm Dis (1993) 1.48
The dietary fat--breast cancer hypothesis is alive. JAMA (1989) 1.48
Invasive cervical cancer and intrauterine device use. Int J Epidemiol (1991) 1.45
Laterality of breast cancer in the United States. Cancer Causes Control (1996) 1.44
Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol (2013) 1.43
Serum hormone levels in relation to reproductive and lifestyle factors in postmenopausal women (United States). Cancer Causes Control (1998) 1.43
CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst (1997) 1.43
Cancer mortality in U.S. counties with petroleum industries. Science (1977) 1.41